Apr 26, 2024, 06:33
Emma Groarke on Ruxolitinib Study for Refractory T-LGL Leukemia from France
Emma Groarke, Hematologist at the National Institutes of Health (NIH), shared a post on X/Twitter:
“Nice paper from France in British Journal of Haematology on a series of relapsed/refractory T- Large granular lymphocytic leukemia (LGL) patients treated with Ruxolitinib.
Some response observed in 86% though complete response in 14%.
A potentially good option for patients going forward.”
Additional information.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 28, 2024, 12:21
Sep 28, 2024, 12:05
Sep 28, 2024, 10:00
Sep 28, 2024, 08:49
Sep 28, 2024, 08:41